US Antiemetics Market Research Report By Drug Class (Serotonin 5-HT3 Receptor Antagonists, Dopamine Antagonists, Antihistamines, Cannabinoids, Neurokinin-1 Receptor Antagonists), By Route of Administration (Oral, Intravenous, Transdermal, Rectal, Subcutaneous), By Indication (Chemotherapy-Induced Nausea, Postoperative Nausea and Vomiting, Motion Sickness, Pregnancy-Related Nausea, Radiation-Induced Nausea) and By End User (Hospitals, Clinics, Homecare Settings, Pharmacies) - Forecast to 2035

US Antiemetics Market Overview

Market Size and Growth

As per MRFR analysis, the US Antiemetics Market Size was estimated at 7.56 (USD Billion) in 2023. The US Antiemetics Market Industry is expected to grow from 8.5 (USD Billion) in 2024 to 14 (USD Billion) by 2035. The US Antiemetics Market CAGR (growth rate) is expected to be around 4.641% during the forecast period (2025 - 2035).

Key Market Trends

The US antiemetics market is currently experiencing several key trends driven by a growing demand for effective nausea and vomiting treatment options. The increasing prevalence of conditions that cause emesis, such as chemotherapy-induced nausea and vomiting (CINV) and post-operative nausea, is a significant market driver. Efforts by healthcare providers to improve patient management, especially in oncology and surgery, have led to heightened usage of antiemetics.

Additionally, there is a shift towards personalized medicine, where treatments are tailored to individual patient responses, optimizing therapeutic outcomes. Opportunities exist in the development of novel drug formulations, including those that can target specific receptors or pathways involved in emesis. The growing interest in non-pharmacological solutions, like acupuncture and behavioral therapies, also highlights avenues for complementary approaches alongside existing drug therapies.

Furthermore, the US Food and Drug Administration (FDA) is actively reviewing and approving new antiemetic agents, which encourages innovation while addressing market demand. In recent times, the trend towards over-the-counter antiemetic medications has gained traction, providing consumers with greater access to these treatments. This shift reflects an increase in awareness and willingness among individuals to manage mild to moderate nausea independently.

Additionally, there is a growing focus on education about the side effects of existing medications, prompting patients to seek integrated solutions. The confluence of these factors is shaping the US antiemetics market, aligning it with both clinical needs and patient preferences.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

US Antiemetics Market Drivers

Rising Incidence of Nausea-Related Conditions

The US Antiemetics Market Industry is experiencing significant growth due to an increasing prevalence of nausea-related conditions such as cancer, gastrointestinal disorders, and migraine. According to the National Cancer Institute, it is estimated that there will be around 1.9 million new cancer cases diagnosed in the United States in 2021 alone. Many cancer patients experience nausea due to chemotherapy treatments, which drives the demand for effective antiemetic medications.

Moreover, the American Gastroenterological Association reports that approximately 35 percent of individuals suffering from gastrointestinal disorders also report persistent nausea, further contributing to market demands. Pharmaceutical companies such as Merck and GlaxoSmithKline have recognized these trends, investing heavily in Research and Development to create innovative treatments. These companies are focusing on developing new drugs with enhanced efficacy and fewer side effects, which is essential given the growing patient population suffering from these debilitating conditions.

The rise in diagnosed cases and the need for effective therapeutics strongly support the growth of the US Antiemetics Market.

Advancements in Drug Formulation and Delivery

Technological advancements in drug formulation and delivery mechanisms are significantly influencing the US Antiemetics Market Industry. New formulations, such as liposomal or extended-release antiemetic medications, enhance patient compliance and allow for optimized dosing regimens. Organizations like the Food and Drug Administration (FDA) have been actively approving innovative delivery systems. The FDA approved a novel sublingual antiemetic drug in recent years, which has shown increased bioavailability and faster onset of action, thus improving treatment outcomes.

This trend towards advanced drug delivery systems is expected to drive the market, as patients are increasingly seeking more efficient and convenient treatment options.

Increased Awareness and Diagnosis of Nausea-Related Disorders

Awareness campaigns and enhanced diagnostic capabilities are also propelling the US Antiemetics Market Industry forward. Organizations like the American Society of Clinical Oncology have raised awareness about nausea management in cancer care, prompting both healthcare professionals and patients to seek better diagnosis and treatment options. As awareness increases, it leads to better diagnosis of nausea-related conditions, which in turn increases the number of prescriptions for antiemetics.

Statistically, there has been a reported 20 percent increase in antiemetic prescriptions over the past five years as healthcare providers better identify the need for these medications in treatment plans, supporting the overall growth of the market.

Growing Geriatric Population Prone to Nausea

The demographic shift towards an aging population in the United States is a significant driver for the US Antiemetics Market Industry. According to the Administration for Community Living, roughly 54 million Americans aged 65 and older were reported in 2019, with projections suggesting this number will rise to over 80 million by 2040. Elderly individuals are more susceptible to conditions causing nausea, such as chronic illnesses and comorbidities.

This demographic change creates a higher demand for antiemetic therapies, necessitating a responsive approach from pharmaceutical companies. Major players such as Pfizer and Johnson & Johnson are allocating substantial resources to Research and Development focused on elder-specific antiemetic formulations, catering directly to this growing need.

US Antiemetics Market Segment Insights

Antiemetics Market Drug Class Insights

The US Antiemetics Market showcases a diverse landscape within the Drug Class segment, which plays a vital role in addressing various types of nausea and vomiting. This segment exhibits a segmented structure, comprising Serotonin 5-HT3 Receptor Antagonists, Dopamine Antagonists, Antihistamines, Cannabinoids, and Neurokinin-1 Receptor Antagonists. Each of these classes addresses specific causes and pathways associated with emesis, making them crucial in clinical treatment practices across various settings.

Serotonin 5-HT3 Receptor Antagonists are particularly significant, primarily used in managing chemotherapy-induced nausea and postoperative vomiting, highlighting their importance in oncological therapies and surgical recovery. These drugs act by blocking serotonin receptors in the central nervous system and gastrointestinal tract, providing effective relief for patients undergoing intense treatment regimens. Additionally, Dopamine Antagonists are valued for their broad-spectrum efficacy against different types of nausea, including that experienced in motion sickness and due to gastrointestinal disturbances.

Their mechanism involves inhibiting dopamine receptors in the brain, which helps mitigate symptoms effectively. Antihistamines have long been a staple in the treatment of motion sickness and allergies, reflecting their longstanding presence in the market. Their action primarily centers on blocking histamine receptors, which can provide relief from symptoms associated with travel and allergic reactions. Cannabinoids have emerged as a novel class of agents in recent years, particularly in the context of chronic conditions such as cancer and HIV/AIDS.

By interacting with the endocannabinoid system, they offer alternative solutions for patients who may not find relief from traditional treatments. Neurokinin-1 Receptor Antagonists are gaining traction due to their effectiveness in preventing acute and delayed nausea in patients undergoing chemotherapy. Their unique action on the neurokinin-1 receptor within the central nervous system makes them invaluable in comprehensive antiemetic therapy. The combination of these various drug classes indicates a robust and continually evolving market aimed at improving patient outcomes and addressing unmet medical needs in the realm of nausea and vomiting management.

The continuous innovation in drug development, along with rising healthcare expenditures and an aging population in the US, will likely further propel the growth within this critical Drug Class segment of the US Antiemetics Market. As healthcare providers seek effective management strategies for nausea and vomiting, the importance of each drug class will remain a focal point for ongoing research and development efforts in the industry, signifying the dynamic nature of the US Antiemetics Market overall.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Antiemetics Market Route of Administration Insights

The Route of Administration segment within the US Antiemetics Market plays a crucial role in addressing the varying needs of patients requiring antiemetic therapies. Different administration methods cater to diverse patient populations and clinical situations. Oral administration, being the most common route, ensures ease of use and accessibility for patients, making it a primary choice for managing nausea and vomiting. Intravenous administration is significant for acute situations, allowing for rapid onset of action, especially in hospitalized settings.

Transdermal patches provide a convenient alternative, offering sustained drug release and higher compliance rates among patients who may struggle with oral intake. Rectal administration, while less commonly discussed, presents an important option for patients unable to take medications orally due to nausea or vomiting, particularly in pediatrics. Subcutaneous routes facilitate self-administration and can be effective in settings where intravenous access is challenging. The choice of route significantly impacts treatment effectiveness, patient adherence, and overall therapeutic outcomes, making the Route of Administration a vital component of the US Antiemetics Market landscape.

With ongoing advancements in drug delivery systems and patient-centered approaches, this segment continues to evolve, presenting both challenges and opportunities in the competitive market.

Antiemetics Market Indication Insights

The US Antiemetics Market segmentation under the Indication category addresses various conditions requiring antiemetic treatment, reflecting significant healthcare needs within the population. Chemotherapy-Induced Nausea is a key area, driven by the rising incidence of cancer and subsequent treatments, requiring effective nausea management to enhance patient quality of life. Postoperative Nausea and Vomiting is also a critical segment, often affecting surgical patients, necessitating efficient solutions to improve recovery experiences.

Motion Sickness remains prevalent among travelers, creating demand for effective treatments to alleviate symptoms during transit. Pregnancy-Related Nausea presents a unique challenge, as it is a common condition among expectant mothers, requiring safe and effective remedies to support maternal well-being. Lastly, Radiation-Induced Nausea constitutes an important area of focus due to the ongoing use of radiation therapy in cancer treatment. The diverse landscape of indications indicates a broad necessity for innovative antiemetic therapies tailored to specific patient circumstances, driving advancements in the US Antiemetics Market.

Furthermore, ongoing research and development efforts aim to enhance treatment efficacy, responding to the nuanced needs of affected individuals across these various conditions.

Antiemetics Market End User Insights

The US Antiemetics Market has shown notable segmentation based on end users, primarily encompassing Hospitals, Clinics, Homecare Settings, and Pharmacies, each playing a vital role in the distribution and utilization of antiemetic drugs. Hospitals serve as a central hub, dealing with complex cases requiring acute management of nausea and vomiting, thereby significantly driving demand for effective antiemetics. Clinics, on the other hand, offer treatment options for outpatients, catering to those with less severe ailments and providing essential support for chronic conditions.

Homecare Settings are increasingly recognized for their importance due to the rising trend of personalized care, allowing patients to manage their symptoms in a comfortable environment, which enhances adherence to treatment protocols. Pharmacies remain a critical access point for patients seeking over-the-counter options, supporting widespread availability and education on antiemetic use. Collectively, these end users contribute to a comprehensive network ensuring that patients receive necessary care, reflecting broad market penetration and varying consumer needs across the healthcare continuum.

The growing emphasis on patient-centered care and advancements in therapeutic options will likely further influence the evolution and dynamics of these segments within the US Antiemetics Market.

US Antiemetics Market Key Players and Competitive Insights

The US Antiemetics Market is characterized by a dynamic landscape, driven by an increasing demand for effective treatment options to combat nausea and vomiting associated with various medical conditions, including chemotherapy, surgery, and motion sickness. This market is witnessing substantial growth due to rising healthcare expenditures, more advanced drug formulations, and heightened awareness about the availability of antiemetic therapies. Competitive dynamics are shaped by the constant evolution of product offerings, the emphasis on clinical effectiveness, and the strategic maneuvering of key players within the sector.

Innovation plays a pivotal role, with companies striving to expand their portfolios and improve patient outcomes by developing new drugs and therapies tailored to specific needs. Merck and Co has established a significant presence in the US Antiemetics Market, capitalizing on its robust research and development capabilities to deliver effective solutions. The company boasts a strong pipeline of antiemetic drugs, which are backed by extensive clinical trials demonstrating their efficacy in alleviating nausea and vomiting. Merck's strength lies in its ability to leverage its wide-reaching distribution network and partnerships with healthcare professionals to enhance patient accessibility to its antiemetic medications.

Additionally, its commitment to innovation ensures that the company remains competitive by continuously updating its product offerings and integrating the latest scientific advancements to optimize treatment outcomes. Bristol Myers Squibb has a notable market presence in the US Antiemetics Market, primarily through its focus on providing high-quality therapies aimed at managing nausea and vomiting in patients undergoing cancer treatments. The company is recognized for its key products that are designed to effectively address these symptoms, ensuring patient adherence to cancer regimens.

Bristol Myers Squibb has invested significantly in research and development, which has enhanced its portfolio with innovative solutions tailored for specific patient populations. The company’s strategic mergers and acquisitions have further solidified its competitive stance, allowing for the integration of complementary products and widening its market reach. Bristol Myers Squibb’s dedication to advancing antiemetic care is evident through its collaboration with healthcare providers, which helps to improve treatment processes and patient outcomes across the United States.

Key Companies in the US Antiemetics Market Include

• Merck and Co


• Bristol Myers Squibb


• Novartis


• AstraZeneca


• GlaxoSmithKline


• Gilead Sciences


• Eli Lilly and Company


• Pfizer


• Amgen


• Roche


• AbbVie


• Sanofi


• Johnson and Johnson


• Mylan


• Teva Pharmaceuticals

US Antiemetics Market Industry Developments

Recent developments in the US Antiemetics Market indicate a growing focus on innovative therapies and expanded accessibility. Companies like Merck and Co., Bristol Myers Squibb, Novartis, AstraZeneca, GlaxoSmithKline, and Gilead Sciences are actively engaging in Research and Development initiatives to enhance their product portfolios. Notably, in April 2023, Eli Lilly and Company launched an advanced antiemetic drug, which has positively impacted patient outcomes and market acceptance.

In terms of mergers and acquisitions, AbbVie’s acquisition of a biotechnology firm in March 2022, aimed at enhancing antiemetic therapies, has drawn attention, reflecting a strategic shift towards consolidating strengths in this domain. Market valuations have continued to rise, with Pfizer and Amgen reporting increased revenues due to the growing demand for innovative antiemetic treatments following the surge in chemotherapy use. Furthermore, regulatory changes and increased awareness regarding nausea treatment options have accelerated market growth, encouraging pharmaceutical firms to invest heavily in this segment.

These dynamics are expected to shape the US Antiemetics Market landscape significantly in the coming years.

US Antiemetics Market Segmentation Insights

Antiemetics Market Drug Class Outlook

• Serotonin 5-HT3 Receptor Antagonists


• Dopamine Antagonists


• Antihistamines


• Cannabinoids


• Neurokinin-1 Receptor Antagonists

Antiemetics Market Route of Administration Outlook

• Oral


• Intravenous


• Transdermal


• Rectal


• Subcutaneous

Antiemetics Market Indication Outlook

• Chemotherapy-Induced Nausea


• Postoperative Nausea and Vomiting


• Motion Sickness


• Pregnancy-Related Nausea


• Radiation-Induced Nausea

Antiemetics Market End User Outlook

• Hospitals


• Clinics


• Homecare Settings


• Pharmacies

Report Attribute/Metric Source:	Details
MARKET SIZE 2018	7.56(USD Billion)
MARKET SIZE 2024	8.5(USD Billion)
MARKET SIZE 2035	14.0(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	4.641% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	Merck and Co, Bristol Myers Squibb, Novartis, AstraZeneca, GlaxoSmithKline, Gilead Sciences, Eli Lilly and Company, Pfizer, Amgen, Roche, AbbVie, Sanofi, Johnson and Johnson, Mylan, Teva Pharmaceuticals
SEGMENTS COVERED	Drug Class, Route of Administration, Indication, End User
KEY MARKET OPPORTUNITIES	Growing demand for nausea relief, Expansion of preventive therapies, Increased use in oncology treatments, Development of innovative formulations, Rising awareness on medication options
KEY MARKET DYNAMICS	rising incidence of nausea disorders, increasing preference for oral medications, advancements in drug formulations, growing acceptance of preventive therapies, expanding geriatric population
COUNTRIES COVERED	US